

PROTEIN DESIGN LABS INC/DE  
Form 8-K  
December 02, 2003

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 1, 2003**

**PROTEIN DESIGN LABS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>		<b>000-19756</b>		<b>94-3023969</b>
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
<b>34801 Campus Drive Fremont, California 94555</b>				
(Address of principal executive offices) (Zip Code)				
Registrant's telephone number, including area code: <b>(510) 574-1400</b>				

**Not Applicable**

(Former name or former address, if changed since last report)



**Item 5. Other Events**

On December 1, 2003, Protein Design Labs, Inc. ( PDL ) issued a press release regarding an agreement in principle to resolve a dispute relating to PDL s antibody humanization patents and certain of Genentech s humanized antibodies. A copy of PDL s press release is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits**

(c) Exhibits

99.1 Press Release dated December 1, 2003.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTEIN DESIGN LABS, INC.**

Date: December 1, 2003

By: /s/ Sergio Garcia-Rodriguez  
Sergio Garcia-Rodriguez  
Vice President, Legal, General Counsel and  
Assistant Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated December 1, 2003.